PFP ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	4

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02748798 (ClinicalTrials.gov)	November 10, 2020	19/4/2016	Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders	Developing Optimal Parameters for Hyperpolarized Noble Gas (3He and 129Xe) and Inert Fluorinated Gas Magnetic Resonance Imaging of Lung Disorders	Lung Transplant;Lung Resection;Lung Cancer;Asthma;Cystic Fibrosis;Chronic Obstructive Pulmonary Disease;Emphysema;Mesothelioma;Asbestosis;Pulmonary Embolism;Interstitial Lung Disease;Pulmonary Fibrosis;Bronchiectasis;Seasonal Allergies;Cold Virus;Lung Infection;Pulmonary Hypertension;Pulmonary Dysplasia;Obstructive Sleep Apnea	Drug: HP 3He;Drug: HP 129Xe;Drug: PFP;Drug: SF6;Device: 129Xe Small and Large Human Lung Coil;Device: 3He Human Lung Coil;Device: PFP and SF6 Human Lung Coil	Thunder Bay Regional Research Institute	Thunder Bay Regional Health Sciences Centre;St. Joseph's Care Group;Lakehead University	Recruiting	18 Years	N/A	All	160	Early Phase 1	Canada
2	NCT03482960 (ClinicalTrials.gov)	May 29, 2018	23/3/2018	Comparison of 129Xe MRI With 19F MRI in CF Lung Disease	Comparison of 129Xe MRI With 19F MRI in CF Lung Disease	Cystic Fibrosis	Drug: Hyperpolarized Xenon gas;Drug: PFP	University of North Carolina, Chapel Hill	Cystic Fibrosis Foundation	Completed	18 Years	N/A	All	11	Early Phase 1	United States
3	NCT03497117 (ClinicalTrials.gov)	August 25, 2015	29/3/2018	19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation	19F Magnetic Resonance Imaging of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation	Cystic Fibrosis	Device: Lung Clearance Index;Drug: MRI with PFP	University of North Carolina, Chapel Hill	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Terminated	18 Years	99 Years	All	5	Early Phase 1	United States
4	NCT03489590 (ClinicalTrials.gov)	July 1, 2015	29/3/2018	19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis	19F Magnetic Resonance Imaging to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: PFP	University of North Carolina, Chapel Hill	NULL	Completed	18 Years	99 Years	All	42	Early Phase 1	United States